DDInter624 DDInter1789
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Thalidomide
Efavirenz {u} (Compound) causes {v} (Side Effect) Loss of consciousness
Loss of consciousness {u} (Side Effect) is caused by {v} (Compound) Thalidomide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Menadione
Menadione {u} (Compound) resembles {v} (Compound) Thalidomide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Thioridazine
Thioridazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Efavirenz {u} (Compound) causes {v} (Side Effect) Loss of consciousness
Loss of consciousness {u} (Side Effect) is caused by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Efavirenz {u} (Compound) causes {v} (Side Effect) Nail disorder
Nail disorder {u} (Side Effect) is caused by {v} (Compound) Saquinavir
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Efavirenz {u} (Compound) causes {v} (Side Effect) Lightheadedness
Lightheadedness {u} (Side Effect) is caused by {v} (Compound) Procainamide
Procainamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) downregulates {v} (Gene) TGFBR2
TGFBR2 {u} (Gene) is upregulated by {v} (Compound) Thalidomide
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is associated with {v} (Gene) TNF
TNF {u} (Gene) is bound by {v} (Compound) Thalidomide
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Thalidomide (Compound)
Efavirenz (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Menadione (Compound) and Menadione (Compound) resembles Thalidomide (Compound)
Efavirenz (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Thioridazine (Compound) and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Efavirenz (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Thalidomide (Compound)
Efavirenz (Compound) causes Nail disorder (Side Effect) and Nail disorder (Side Effect) is caused by Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Efavirenz (Compound) causes Lightheadedness (Side Effect) and Lightheadedness (Side Effect) is caused by Procainamide (Compound) and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) downregulates TGFBR2 (Gene) and TGFBR2 (Gene) is upregulated by Thalidomide (Compound)
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is associated with TNF (Gene) and TNF (Gene) is bound by Thalidomide (Compound)